CD Bioparticles
CD Bioparticles is a privately held US manufacturer of magnetic particles, nanoparticles, and bead-based kits, plus custom drug delivery and vaccine development services, serving pharmaceutical, biotech, clinical, and environmental laboratories across North America and Europe.
- Company typePrivate
- Founded2009
- HeadquartersShirley, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CD Bioparticles does
CD Bioparticles is a privately held US-based manufacturer and supplier of magnetic particles, nanoparticles, and bead-based kits serving pharmaceutical, biotechnology, clinical diagnostics, and environmental testing laboratories. Headquartered in Shirley, New York, with an additional New York presence tied to its 2026 vaccine services launch, the company has operated for over 10 years and reports serving thousands of research and commercial clients globally across North America and Europe. Its portfolio spans Absolute Mag™ magnetic particles (streptavidin, affinity, ion-exchange, lanthanide-based, silica), a broad nanoparticle catalog (spherical gold, gold nanorods, silver, silica, quantum dots, upconverting nanoparticles, titania, polymer, nanozymes, cellulose), MagIso™ nucleic acid isolation particles, fluorescence-encoded multiplex beads capable of detecting up to 100 analytes simultaneously, and a comprehensive line of beads-based kits covering chromatin immunoprecipitation, ELISA, virus purification, cell isolation, and immunoprecipitation. Proprietary platform technologies include an organ-targeted lipid nanoparticle (LNP) system using novel structured cationic and ionizable lipids for extrahepatic RNA delivery and an outer membrane vesicle (OMV) engineering platform that combines synthetic biology with bacterial genome editing to produce bacterial vaccines at claimed production costs at least five times lower than conventional methods.
The company operates a hybrid go-to-market combining direct e-commerce sales through its multilingual storefront (English, German, Japanese, Korean) with a distributor network covering 11 countries and a sales-led motion for custom services such as antibody immobilization, immunomagnetic bead preparation, drug targeting and delivery, assay development (latex immunoturbidimetric, colloidal gold lateral flow, quantum dot lateral flow, chemiluminescent immunoassay), characterization, and animal model validation. Revenue is generated primarily through transactional catalog product sales (one-time purchase, pay-as-you-go with promotional bundles such as the BOGO Magnetic Rack Separator offer) and fee-for-service custom engagements, with all pricing quote-based and not publicly disclosed. Recent strategic activity has been concentrated in the first quarter of 2026 with three distinct launches — the OMV-Based Bacterial Vaccines Development platform (January 2026), Magnetic Solid-Phase Extraction polymer magnetic particles (February 2026), and Extrahepatic RNA Delivery services (March 2026) — signaling an explicit pivot up the value chain from consumable reagents into therapeutic-enabling CRO/CDMO service offerings for pharma and biotech developers.
CD Bioparticles firmographics
Firmographics- Name
- CD Bioparticles
- Legal name
- CD Bioparticles
- Website
- https://cd-bioparticles.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- CD Bioparticles is a privately held US manufacturer of magnetic particles, nanoparticles, and bead-based kits, plus custom drug delivery and vaccine development services, serving pharmaceutical, biotech, clinical, and environmental laboratories across North America and Europe.
- Ownership category
- akta.pro rank
CD Bioparticles industry classification
Industry- Product category
- Biomedical Research Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Nanotechnology (541713)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)
- akta.pro secondary industries
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
Keywords
Where CD Bioparticles is headquartered
LocationHeadquarters
- HQ city
- Shirley
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CD Bioparticles business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Product Sales (Magnetic Particles and Nanoparticles): Direct sales of magnetic particles, nanoparticles (gold, silver, silica, polymer, quantum dots, upconverting), and beads-based kits to pharmaceutical, biotech, clinical, and environmental laboratories worldwide via e-commerce and distributors.
- Custom Services: Fee-for-service offerings including antibody immobilization, immunomagnetic beads preparation, drug targeting and delivery, assays development, and characterization services for specialized client needs.
- Extrahepatic RNA Delivery Services: Comprehensive service offering utilizing organ-targeted LNP platform with customizable targeting strategies, in vitro/in vivo validation, and safety analysis for nucleic acid therapeutics.
- OMV-Based Bacterial Vaccine Development Services: End-to-end vaccine development services from pathogen strain acquisition and OMV extraction to engineered OMV design, quality control, and GLP-compliant preclinical evaluation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard product catalog with promotional offers |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
CD Bioparticles product offering
Product offeringCore offering
CD Bioparticles manufactures and supplies magnetic particles, nanoparticles (gold, silver, silica, quantum dots, upconverting, polymer), and bead-based kits for biomedical applications including immune detection, isolation, drug delivery, and diagnostic assay development. The company also offers custom services such as drug targeting and delivery, antibody immobilization, assays development, and proprietary platforms including organ-targeted lipid nanoparticles for RNA delivery and outer membrane vesicle-based bacterial vaccine development.
Product overview
CD Bioparticles is a manufacturer and supplier of magnetic particles, nanoparticles, and related laboratory products serving the pharmaceutical, biotechnology, clinical, and research sectors. The company's portfolio is organized into core product categories including Magnetic Particles (such as Absolute Mag™ Streptavidin and Gold Coated Magnetic Nanoparticles), Nanoparticles (including Spherical Gold Nanoparticles, Quantum Dots, Upconverting Nanoparticles, Fluorescent Silica Particles, and Nanozyme), Beads Based Kits and Devices, and Chromatography Resins. The portfolio features specialized sub-brands like Absolute Mag™ for magnetic particles, MagIso™ for nucleic acid isolation, and Fluorescence-Encoded Multiplex Beads for multiplexed detection. In addition to products, CD Bioparticles offers comprehensive custom services including Drug Targeting and Delivery (particularly Extrahepatic RNA Delivery Services using organ-targeted LNP platform), OMV-Based Bacterial Vaccines Development (combining synthetic biology with genome editing), Antibody Immobilization, Assays Development Services, and Characterization/Animal Model Validation. The company recently launched Magnetic Solid-Phase Extraction (MSPE) Particles for high-throughput sample preparation. Custom services are available for surface functionalization, fluorescent modification, antibody/nucleic acid conjugation, and gold nanoparticle conjugation to meet client specifications.
Differentiator
Problem solved
Functional benefit
Products and services
- Magnetic Particles Comprehensive range of magnetic particles including Active, Affinity, Basic, Ion-exchange, Lanthanide-Based, Hydrophobe, and Silica Magnetic Particles, as well as Conjugation Kits, designed for immune detection, cell isolation, and nucleic acid extraction in laboratory and research applications.
- Nanoparticles Wide range of nanoparticles including Spherical Gold Nanoparticles, Gold Nanorods, Silver Nanoparticles, Special Shape Particles, Silica Particles, Quantum Dots, Upconverting Nanoparticles, Titania Nanoparticles, Polymer Particles, Graphene and Carbon Nanotube, Agarose Particles, Additive Powders, Nanozyme, and Cellulose Nanoparticles for diagnostic, imaging, and biomedical applications.
- Beads Based Kits and Devices Complete selection of kits including Chromatin Immunoprecipitation Kit, Protein Labeling/Isolation/Purification Kit, Antibody Fragmentation Kits, Bead-Based ELISA Kit, Mycotoxin Clean-up Kit, Virus Purification Kit, Homogenous Chemiluminescence Particles Based Assay Kit, Phosphoprotein Detection Kit, Pull-Down Kit, Cell Isolation, Organelles Isolation, DNA & RNA Extraction and Purification, and Immunoprecipitation Kit.
- Chromatography Resins Resins for chromatographic separation and purification applications in pharmaceutical and biotech research.
- Magnetic Solid-Phase Extraction (MSPE) Particles Polymer magnetic particles including Absolute Mag HLB and Absolute Mag MCX products, designed for high-throughput sample preparation workflows in pharmaceutical, biotech, clinical, and environmental laboratories, featuring recovery rates of 75-90% and 15-minute workflow times compatible with automated liquid handling systems.
- Extrahepatic RNA Delivery Services Comprehensive services utilizing novel structured cationic and ionizable lipids with customizable targeting strategies using ligands such as antibodies and peptides, including in vitro/in vivo validation and safety/stability analysis for targeted delivery of RNA therapeutics to extrahepatic organs including lungs, spleen, brain, and lymph nodes.
- OMV-Based Bacterial Vaccines Development Platform Advanced engineering platform combining synthetic biology with bacterial genome editing to develop scalable, safe, and immunogenic outer membrane vesicle-based bacterial vaccines for infectious disease and oncology research, with claimed production costs at least five times lower than conventional methods, providing end-to-end solutions from pathogen strain acquisition and OMV extraction to engineered OMV design, quality control, and GLP-compliant preclinical evaluation.
- Antibody Immobilization Services Custom services including antibody microarray printing, immobilization of antibodies on beads/macro carriers/silicon surfaces, custom gold nanoparticle conjugation, and custom upconverting nanoparticle conjugation for diagnostic and research applications.
- Assays Development Services Development services for latex immunoturbidimetric assay, colloidal gold lateral flow assay, quantum dot lateral flow assay, homogeneous luminescence assay, upconversion nanoparticle lateral flow assay, and magnetic particle chemiluminescent immunoassay.
- Drug Targeting and Delivery Services Services including nucleic acid delivery particles, magnetic sodium alginate hydrogel particles, and bio-targeted small molecules conjugated magnetic nanoparticles for drug targeting and delivery applications.
- Immunomagnetic Beads Preparation Services Services including magnetic beads bioconjugation and modification for immunomagnetic applications in research and diagnostics.
- Custom Imaging Contrast Agents Custom contrast agents for computed tomography (CT), ultrasound imaging, magnetic resonance imaging (MRI), and near-infrared (NIR) fluorescent imaging for diagnostic and research applications.
- Animal Model Validation Services In vivo validation services using animal models for nanoparticle and magnetic particle-based products and therapies.
Quantifiable outcome
- MSPE particles achieve 75-90% recovery rates with 15-minute workflow time
- +2 more outcomes
Companies that use CD Bioparticles
Customer profileSegments3 records
Ideal customer profiles3 records
CD Bioparticles technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
CD Bioparticles partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights6 records
CD Bioparticles competitors and assessment
Company assessmentDirect peers
- Polysciences: Specialty manufacturer of polymer, magnetic, and fluorescent microparticles and nanoparticles for life science, biomedical, and diagnostic use. Directly comparable catalog and custom conjugation/CDMO services to CD Bioparticles.
- Bangs Laboratories: Producer of polymeric and magnetic microparticles, beads, and particles for diagnostics, life science research and biomedical applications. Closely comparable specialty particle platform with custom surface functionalization.
- Spherotech: Manufacturer of uniform microparticles and nanoparticles, including magnetic, fluorescent, and colored beads for diagnostic and research use. Directly comparable portfolio for multiplex assays and bead-based kits.
- Ocean NanoTech: Supplier of magnetic nanoparticles, quantum dots, fluorescent nanoparticles and related products for biomedical, diagnostic, and research applications. Direct overlap on nanoparticle catalog and conjugation services.
- Miltenyi Biotec: Provider of magnetic bead-based cell separation, sample preparation, and flow cytometry solutions for biomedical research and cell therapy. Comparable magnetic bead platforms and bead-based kits for life science use.
Broad incumbents
- Bio-Rad Laboratories: Global life sciences and clinical diagnostics leader offering Bio-Plex multiplex magnetic bead assays, magnetic separators, and particle-based reagents. Broader portfolio but overlapping capability in bead-based multiplex assays and magnetic particle tools.
- Thermo Fisher Scientific: Global life science tools giant with Dynabeads magnetic bead products, particle-based reagents, and custom services across pharma, biotech, and clinical markets. Largest comparable incumbent in the magnetic particle space.
- Merck KGaA (Sigma-Aldrich): Major life science reagent and tools supplier offering magnetic nanoparticles, gold nanoparticles, and bead-based products. Broader catalog and global distribution but overlapping magnetic and nanoparticle product lines.
- Cytiva: Scaled life sciences tools provider offering magnetic bead-based sample prep, purification and chromatography solutions serving biopharma R&D and manufacturing. Overlaps with CD Bioparticles in magnetic particle workflows and chromatography resins.
Emerging players
- MagBio Genomics: Specialty supplier of magnetic bead-based nucleic acid extraction and diagnostic sample prep products. Comparable focus on magnetic particle workflows for life science and clinical use, smaller scale than incumbent peers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CD Bioparticles social profiles
Digital presenceCD Bioparticles financial estimates
Financial estimateRevenue estimate
Valuation estimate
CD Bioparticles leadership team
Management profileNumber of profiles
CD Bioparticles funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CD Bioparticles M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CD Bioparticles
What does CD Bioparticles do?
CD Bioparticles manufactures and supplies magnetic particles, nanoparticles (gold, silver, silica, quantum dots, upconverting, polymer), and bead-based kits for biomedical applications including immune detection, isolation, drug delivery, and diagnostic assay development. The company also offers custom services such as drug targeting and delivery, antibody immobilization, assays development, and proprietary platforms including organ-targeted lipid nanoparticles for RNA delivery and outer membrane vesicle-based bacterial vaccine development.
Is CD Bioparticles a public or private company?
CD Bioparticles is a private company. It is classified as unknown and is currently operating.
When was CD Bioparticles founded?
CD Bioparticles was founded in 2009. It employs 51 to 100 people.
Where is CD Bioparticles based?
CD Bioparticles is headquartered in Shirley, United States, in the North America region.
How does CD Bioparticles make money?
Four revenue lines are on record. Product Sales (Magnetic Particles and Nanoparticles) is the primary driver. The others are custom Services, extrahepatic RNA Delivery Services and OMV-Based Bacterial Vaccine Development Services.
Who are CD Bioparticles's main competitors?
Direct peers on record are Polysciences, Bangs Laboratories, Spherotech, Ocean NanoTech and Miltenyi Biotec. Broad incumbents are Bio-Rad Laboratories, Thermo Fisher Scientific, Merck KGaA (Sigma-Aldrich) and Cytiva. MagBio Genomics is listed as an emerging player.
Does CD Bioparticles have an API?
No public API is recorded for CD Bioparticles.
What industry is CD Bioparticles in?
CD Bioparticles's product category is Biomedical Research Reagents. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.